Trial Profile
Phase II, proof-of-concept trial of VX 661 in combination with ivacaftor in patients with cystic fibrosis who have one copy of the F508del mutation and one copy of the G551D mutation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jan 2015
Price :
$35
*
At a glance
- Drugs Ivacaftor (Primary) ; Tezacaftor (Primary)
- Indications Cystic fibrosis
- Focus Proof of concept; Therapeutic Use
- Sponsors Vertex Pharmaceuticals
- 11 Jan 2015 Status changed from recruiting to completed, according to a Vertex Pharmaceuticals media release.
- 21 Oct 2013 New trial record
- 17 Oct 2013 Results from this trial are expected in the first quarter of 2014, according to a Vertex Pharmaceuticals media release.